These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3653231)

  • 21. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
    Appel-Dingemanse S; Lemarechal MO; Kumle A; Hubert M; Legangneux E
    Br J Clin Pharmacol; 1999 May; 47(5):483-91. PubMed ID: 10336571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.
    Nicholls DP; McNeill J; O'Connor PC; Harron DW; Leahey WJ; Shanks RG
    Br J Clin Pharmacol; 1984 Aug; 18(2):215-21. PubMed ID: 6386022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V; Oliver S; Su CA
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration.
    Salvadori C; Ward C; Defrance R; Hopkins R
    Fundam Clin Pharmacol; 1990; 4(1):115-25. PubMed ID: 2341111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of oxybutynin in man.
    Douchamps J; Derenne F; Stockis A; Gangji D; Juvent M; Herchuelz A
    Eur J Clin Pharmacol; 1988; 35(5):515-20. PubMed ID: 3234461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential blockade of alpha-adrenoceptors by indoramin.
    Nicholls DP; O'Connor PC; Harron DW; Leahey WJ; Shanks RG
    Br J Clin Pharmacol; 1984 Jun; 17(6):719-28. PubMed ID: 6146328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemodynamic dose-response effects of intravenous indoramin in acute heart failure complicating myocardial infarction.
    Silke B; Nelson GI; Verma SP; Frais MA; Reynolds G; Jackson N; Taylor SH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S102-6. PubMed ID: 2423781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.
    Wiesel FA; Alfredsson G; Ehrnebo M; Sedvall G
    Eur J Clin Pharmacol; 1980 May; 17(5):385-91. PubMed ID: 7418717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man.
    Flesch G; Müller P; Lloyd P
    Eur J Clin Pharmacol; 1997; 52(2):115-20. PubMed ID: 9174680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
    Cass LM; Efthymiopoulos C; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():1-11. PubMed ID: 10429835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.
    Tremblay D; Dupront A; Ho C; Coussediere D; Lenfant B
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():21-8. PubMed ID: 2292526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs.
    Baxter JG; Brass C; Schentag JJ; Slaughter RL
    J Pharm Sci; 1986 May; 75(5):443-7. PubMed ID: 3735080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Felodipine pharmacokinetics and plasma concentration vs effect relationships.
    Blychert E
    Blood Press Suppl; 1992; 2():1-30. PubMed ID: 1343111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.
    Hinderling PH; Garrett ER; Wester RC
    J Pharm Sci; 1977 Mar; 66(3):314-25. PubMed ID: 845795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the biotransformation of indoramin in the patas monkey.
    Franklin RA; Pierce DM
    Xenobiotica; 1981 Nov; 11(11):755-62. PubMed ID: 7336756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.
    Dominiak P; Grevel J; Abisch E; Grobecker H; Dennler HJ; Welzel D
    Eur J Clin Pharmacol; 1988; 35(1):53-7. PubMed ID: 3146506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.